TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17886090

Group type: EXPERIMENTAL
Intervention: Sodium-bicarbonated mineral water 1
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sodium-bicarbonated mineral water 2
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-mineral water
Number of subjects: 18
Study: 16288079

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0
Study: 12525444

Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine system (LNG‐IUS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (untreated tissue)
Number of subjects: 48
Study: 10914614

Group type: EXPERIMENTAL
Intervention: Isoflavones
Number of subjects: 0
Study: 8985525

Group type: EXPERIMENTAL
Intervention: Henna application
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (non-henna-induced haemolysis)
Number of subjects: 15
Study: 1531285

Group type: EXPERIMENTAL
Intervention: Foscarnet (40 mg/kg every 8 or 12 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acyclovir maintenance following foscarnet induction therapy
Number of subjects: 0
Study: 4061980

Group type: EXPERIMENTAL
Intervention: Terbutaline delivered by tube spacer
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Terbutaline delivered by conventional inhaler
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 31423712

Group type: EXPERIMENTAL
Intervention: High-intensity care (up-titration of oral HF medications including beta-blockers, ACE inhibitors or ARBs, and MRAs)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Usual care (managed according to usual clinical practice)
Number of subjects: 900
Study: 29417902

Group type: EXPERIMENTAL
Intervention: High-dose group (5 × 10^7 haMSCs)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Mid-dose group (2 × 10^7 haMSCs)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low-dose group (1 × 10^7 haMSCs)
Number of subjects: 18
Study: 27335279

Group type: EXPERIMENTAL
Intervention: Thermotherapy (TT) with 48°C water for 90 min
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control intervention with 33°C water
Number of subjects: 16
Study: 25354998

Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells (hMSC)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Allogeneic mesenchymal stem cells (allo-hMSCs)
Number of subjects: 36
Study: 22461463

Group type: EXPERIMENTAL
Intervention: Higher volume-load (strength-power) training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Lower volume-load (speed-power) training
Number of subjects: 18
Study: 19625388

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 18625864

Group type: EXPERIMENTAL
Intervention: Bilateral stimulation of the GPi
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Bilateral stimulation of the CM‐Pf
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Simultaneous thalamic and pallidal stimulation
Number of subjects: 3

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 3
Study: 18538110

Group type: EXPERIMENTAL
Intervention: Depot antipsychotic drugs (DA)
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: History of suicide
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Clozapine use
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Antipsychotic polypharmacy (APP)
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Admissions
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Study site (HK vs. BJ)
Number of subjects: 505
Study: 15182776

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 1000
Study: 11252212

Group type: EXPERIMENTAL
Intervention: Experimental group (n=49) received meal plans, recipes, and nutritional information during monthly group office sessions
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (n=48) followed the National Cholesterol Education Program's Step II‐III diet plan
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Experimental group (n=49)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (n=48)
Number of subjects: 97
Study: 9416938

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg 2 times daily)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg 2 times daily) + Aspirin (325 mg/day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day) + Aspirin (325 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 16
Study: 8295813

Group type: EXPERIMENTAL
Intervention: Clarithromycin 7.5 mg/kg twice daily, maximum 500 mg twice daily (n = 161)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate 13.3 mg/kg three times daily, maximum 500 mg three times daily (n = 177)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 338

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 338
Study: 3091459

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Fragmin)
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Unfractionated heparin (UF heparin)
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Low doses of Fragmin (anti-FXa: 0.2-0.3 U/ml)
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Intraperitoneal application of Fragmin
Number of subjects: 10000
Study: 11443185

Group type: EXPERIMENTAL
Intervention: Canrenoate (200 mg as iv bolus at 2000 h, followed by 200 mg infused in 500 mL saline over 4 h up to 2400 h)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (saline, 1.0 mL as iv bolus at 2000 h, followed by 500 mL over 4 h up to 2400 h)
Number of subjects: 7
Study: 31796695

Group type: EXPERIMENTAL
Intervention: Spanish modified Story Memory Technique (mSMT), 10-session intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 20
Study: 30346495

Group type: EXPERIMENTAL
Intervention: Reminder and Standard Information Booklet
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Reminder and Theory‐Based Leaflet
Number of subjects: 1218

Group type: COMPARATOR
Intervention: Control (no reminder)
Number of subjects: 1218
Study: 26147635

Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.1% ointment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Topical pimecrolimus 1% cream
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both tacrolimus and pimecrolimus
Number of subjects: 40
Study: 25258407

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/day for 14 days
Number of subjects: 30
Study: 22859389

Group type: EXPERIMENTAL
Intervention: Resistance exercise at 75% 1RM, 2× volume (3 × 8, then 6 × 8 repetitions)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Resistance exercise at 75% 1RM, 1× volume (3 × 8, then 6 × 8 repetitions)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Resistance exercise at 40% 1RM, 2× volume (3 × 14, then 6 × 14 repetitions)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Resistance exercise at 40% 1RM, 1× volume (3 × 14, then 6 × 14 repetitions)
Number of subjects: 12
Study: 20207689

Group type: EXPERIMENTAL
Intervention: Rapid diagnostic test
Number of subjects: 7263

Group type: COMPARATOR
Intervention: Microscopy
Number of subjects: 7263
Study: 18793544

Group type: EXPERIMENTAL
Intervention: Creatinine (Crea)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Cystatin C (CyC)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 1/Crea
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Larsson formula
Number of subjects: 105

Group type: COMPARATOR
Intervention: Cockroft and Gault (C&G)
Number of subjects: 105

Group type: COMPARATOR
Intervention: MDRD
Number of subjects: 105
Study: 16041739

Group type: EXPERIMENTAL
Intervention: Atrisin (three capsules/day)
Number of subjects: 65
Study: 11812070

Group type: EXPERIMENTAL
Intervention: Coronary flow velocity reserve < 2.0 (n=109, 26%)
Number of subjects: 417

Group type: COMPARATOR
Intervention: Coronary flow velocity reserve >= 2.0
Number of subjects: 417
Study: 10088846

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (human)
Number of subjects: 47
Study: 7585860

Group type: EXPERIMENTAL
Intervention: Propofol for induction and maintenance of anesthesia
Number of subjects: 1

Group type: COMPARATOR
Intervention: Thiopental/Isolurane
Number of subjects: 1
Study: 2262649

Group type: EXPERIMENTAL
Intervention: Intranasal budesonide, 400 micrograms two times a day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 443772

Group type: EXPERIMENTAL
Intervention: Transfer factor
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 30706457

Group type: EXPERIMENTAL
Intervention: 0.05% tretinoin cream (TRE) every other night
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 10 mg/day oral isotretinoin (ISO)
Number of subjects: 61
Study: 30121097

Group type: EXPERIMENTAL
Intervention: Talking with Teens about Traffic Safety Program (treatment group)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 108
Study: 27018533

Group type: EXPERIMENTAL
Intervention: Intervention aimed at increasing need-satisfying experiences
Number of subjects: 41

Group type: COMPARATOR
Intervention: Neutral comparison
Number of subjects: 41
Study: 25007421

Group type: EXPERIMENTAL
Intervention: Patient-initiated violence reported by caregivers
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Caregiver ratings of hostility expressed toward patients
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Caregiver self-esteem and coping strategies
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Caregiving situation
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Patient characteristics
Number of subjects: 72
Study: 23427748

Group type: EXPERIMENTAL
Intervention: Photoselective vaporization of the prostate (PVP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 0
Study: 20473056

Group type: EXPERIMENTAL
Intervention: 10-mg intramuscular olanzapine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 10-mg orally disintegrating olanzapine tablets
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 3-mg oral risperidone solution
Number of subjects: 42

Group type: COMPARATOR
Intervention: 7.5-mg intramuscular haloperidol
Number of subjects: 42
Study: 17852863

Group type: EXPERIMENTAL
Intervention: NO-generating solution
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control solution (hydrochloric acid pH 1.0)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nitrous acid solution
Number of subjects: 15
Study: 16279576

Group type: EXPERIMENTAL
Intervention: Data Monitoring Committees (DMCs) involvement in trials
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: DMC policies from organizations
Number of subjects: 45
Study: 12649048

Group type: EXPERIMENTAL
Intervention: Dietary advice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of dietary advice and exercise
Number of subjects: 0
Study: 10805203

Group type: EXPERIMENTAL
Intervention: TAA-HFA 75 microg for 6 or 12 months
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: TAA-HFA 225 microg for 6 or 12 months
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: TAA-HFA 75 or 225 microg
Number of subjects: 552
Study: 8980434

Group type: EXPERIMENTAL
Intervention: Stripping of the long saphenous vein
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no stripping)
Number of subjects: 100
Study: 1479709

Group type: EXPERIMENTAL
Intervention: rEPO administered twice a week (group A)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: rEPO administered once a week (group B)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 42
Study: 6463067

Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 to 0.15 mg/kg) with suxamethonium (1 mg/kg)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 to 0.15 mg/kg) with pancuronium (0.075 mg/kg)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Suxamethonium alone
Number of subjects: 37

Group type: COMPARATOR
Intervention: Pancuronium alone
Number of subjects: 37
Study: 30383579

Group type: EXPERIMENTAL
Intervention: PEG 3350
Number of subjects: 102

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 102
Study: 30513095

Group type: EXPERIMENTAL
Intervention: 0.625 mg/d of conjugated equine estrogens (CEE)
Number of subjects: 16053

Group type: EXPERIMENTAL
Intervention: CEE plus 2.5 mg/d of medroxyprogesterone acetate (MPA)
Number of subjects: 16053
Study: 27068807

Group type: EXPERIMENTAL
Intervention: E-care 4 caregivers online intervention
Number of subjects: 84

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 84
Study: 25133471

Group type: EXPERIMENTAL
Intervention: Oxandrolone (0.03 mg/kg per day or 0.06 mg/kg per day)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Complete monosomy Xp
Number of subjects: 65
Study: 22995087

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 6789

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 6789

Group type: EXPERIMENTAL
Intervention: EES
Number of subjects: 6789

Group type: COMPARATOR
Intervention: PES
Number of subjects: 6789
Study: 20153142

Group type: EXPERIMENTAL
Intervention: Cocaine-dependent subjects (CD)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Non-drug-using controls
Number of subjects: 19
Study: 18373019

Group type: EXPERIMENTAL
Intervention: Phototherapy (10000 lux)
Number of subjects: 24
Study: 15716707

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 115
Study: 11834851

Group type: EXPERIMENTAL
Intervention: Mometasone furoate 0.1% with wet-wrap dressings
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle (steroid-free) with wet-wrap dressings
Number of subjects: 20
Study: 9881313

Group type: EXPERIMENTAL
Intervention: Three-hour training session in formulating questions and searching databases
Number of subjects: 108

Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 108
Study: 8037876

Group type: EXPERIMENTAL
Intervention: Testosterone supplementation for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 2525897

Group type: EXPERIMENTAL
Intervention: Transdermal clonidine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Oral atenolol
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: COMPARATOR
Intervention: Transdermal clonidine and Placebo
Number of subjects: 27
Study: 30677506

Group type: EXPERIMENTAL
Intervention: roniciclib plus chemotherapy
Number of subjects: 140

Group type: COMPARATOR
Intervention: placebo plus chemotherapy
Number of subjects: 140
Study: 29136094

Group type: EXPERIMENTAL
Intervention: Multidomain intervention (nutritional and exercise counselling and cognitive training)
Number of subjects: 1680

Group type: COMPARATOR
Intervention: Omega-3 supplementation (800 mg docosahexanoic acid and up to 225 mg eicosapentanoic acid)
Number of subjects: 1680

Group type: EXPERIMENTAL
Intervention: Multidomain intervention plus omega-3 supplementation
Number of subjects: 1680

Group type: COMPARATOR
Intervention: Placebo with usual care
Number of subjects: 1680

Group type: COMPARATOR
Intervention: Omega-3 plus usual care
Number of subjects: 1680
Study: 26508094

Group type: EXPERIMENTAL
Intervention: TMZ/ABT‐888 (40 mg BID ABT‐888 with 75 mg/m² TMZ for 21 days)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: TMZ/ABT‐888 (40 mg BID ABT‐888 with 150-200 mg/m² TMZ for 5 days)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: TMZ/ABT‐888 (both arms)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 225
Study: 24821941

Group type: EXPERIMENTAL
Intervention: Amlodipine±perindopril
Number of subjects: 2069

Group type: COMPARATOR
Intervention: Atenolol±bendroflumethiazide
Number of subjects: 2069

Group type: EXPERIMENTAL
Intervention: XSPI
Number of subjects: 2069

Group type: EXPERIMENTAL
Intervention: XSPI, central systolic blood pressure, central augmentation pressure, central pulse pressure, integral of reservoir pressure
Number of subjects: 2069

Group type: EXPERIMENTAL
Intervention: XSPI, augmentation pressure, central pulse pressure
Number of subjects: 2069

Group type: EXPERIMENTAL
Intervention: XSPI, integral of reservoir pressure
Number of subjects: 2069
Study: 22836034

Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal-weight control subjects
Number of subjects: 22
Study: 20601383

Group type: EXPERIMENTAL
Intervention: Peer-led smoking prevention programme (video and discussion groups)
Number of subjects: 1071

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: Peer-led smoking prevention programme
Number of subjects: 1071
Study: 17427602

Group type: EXPERIMENTAL
Intervention: Psychoeducational Family Interventions (PFI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual integrated interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Different PFI strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Implementation studies
Number of subjects: 0
Study: 16287051

Group type: EXPERIMENTAL
Intervention: Music therapy and routine care
Number of subjects: 64

Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 64
Study: 12058514

Group type: EXPERIMENTAL
Intervention: Occupational therapy training
Number of subjects: 895

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 895
Study: 9865017

Group type: EXPERIMENTAL
Intervention: Metopress-retard 100 mg taken at 8 a.m.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Metopress-retard 100 mg taken at 8 p.m.
Number of subjects: 38
Study: 7783666

Group type: EXPERIMENTAL
Intervention: Sorbitol (2.5 to 20 g in iso-osmolar solutions)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Sorbitol (20 g)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Sorbitol (up to 10 g)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Normal controls (no specific intervention mentioned)
Number of subjects: 113
Study: 2547300

Group type: EXPERIMENTAL
Intervention: Pea fiber (PF) 15 g
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sugar beet fiber (BF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wheat bran (WB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control meal (150 g ground beef, 50 g glucose, 20 g lactulose)
Number of subjects: 0
Study: 1264003

Group type: EXPERIMENTAL
Intervention: Early mobilization
Number of subjects: 113

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 113
Study: 7316247

Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxyzine and Phenylpropanolamine (combined)
Number of subjects: 0
Study: 31274113

Group type: EXPERIMENTAL
Intervention: Internet Support Group (ISG) usage
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Active users contributing with posts or comments
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sociodemographic characteristics
Number of subjects: 48
Study: 28124631

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided drainage
Number of subjects: 60

Group type: COMPARATOR
Intervention: Incision and drainage
Number of subjects: 60
Study: 25317504

Group type: EXPERIMENTAL
Intervention: Core stability exercise
Number of subjects: 29

Group type: COMPARATOR
Intervention: Traditional trunk exercise
Number of subjects: 29
Study: 24986094

Group type: EXPERIMENTAL
Intervention: Glycopyrronium (400 µg, single inhaled supra-therapeutic dose)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73

Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 73
Study: 22818144

Group type: EXPERIMENTAL
Intervention: 30 mg PD‐0299685 daily
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: 60 mg PD‐0299685 daily
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 19070833

Group type: EXPERIMENTAL
Intervention: Cerclage (fFN-positive)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No cerclage (fFN-positive)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cerclage (fFN-negative)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No cerclage (fFN-negative)
Number of subjects: 0
Study: 17334512

Group type: EXPERIMENTAL
Intervention: NCX 4016 (800 mg b.i.d.)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Aspirin (100 mg o.d.)
Number of subjects: 44
Study: 15455743

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) with coronally positioned flap
Number of subjects: 13

Group type: COMPARATOR
Intervention: Coronally positioned flap alone (CPF)
Number of subjects: 13
Study: 11683739

Group type: COMPARATOR
Intervention: DL (dilator technique)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: ND (no dilator technique)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: DL (dilator technique) and ND (no dilator technique)
Number of subjects: 58
Study: 10030463

Group type: EXPERIMENTAL
Intervention: Zatebradine 10 mg i.v. (n = 24)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Isotonic saline (n = 12)
Number of subjects: 36
Study: 8049639

Group type: EXPERIMENTAL
Intervention: Active vitamin/mineral supplementation
Number of subjects: 3318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3318
Study: 3281637

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 31173662

Group type: EXPERIMENTAL
Intervention: Teacher training intervention
Number of subjects: 3435

Group type: COMPARATOR
Intervention: Teacher training plus parental-awareness meetings
Number of subjects: 3435
Study: 28917367

Group type: EXPERIMENTAL
Intervention: 10 weeks of hatha yoga classes
Number of subjects: 50

Group type: COMPARATOR
Intervention: Health education control group
Number of subjects: 50
Study: 25313670

Group type: EXPERIMENTAL
Intervention: HAP-focused physician
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LAP-focused physician
Number of subjects: 0